: Major product approvals are expected in 2026 for Bepirovirsen (Chronic Hepatitis B) and Tebipenem (UTIs).
As of late April 2026, (LSE: GSK / NYSE: GSK) has shifted from being a "disappointing" pharmaceutical giant to a momentum-driven stock. After years of underperformance, shares have surged over 16% in 2026 alone and roughly 59% over the past 12 months , significantly outperforming the FTSE 100. buy gsk shares
GSK remains a staple for income-seeking investors, with management showing a commitment to increasing payouts: : Major product approvals are expected in 2026